1026022-17-2

Upstream product

• 64650-81-3 allyl α-L-rhamnopyranoside 
• 89821-77-2 Allyl 4-O-benzyl-2,3-O-isopropylidene-α-L-rhamnopyranoside 
• 1026022-05-8 O-triisopropylsilyl 4-O-benzyl-2,3-di-O-isopropylidene-α-L-rhamnopyranoside 
• 1026022-06-9 O-triisopropylsilyl 2,3-di-O-isopropylidene-α-L-rhamnopyranoside 
• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 
• 182212-10-8 1-O-allyl-D-xylopyranoside 
• 850004-55-6 (3R,4S,5R)-2-Allyloxy-3,5-bis-benzyloxy-tetrahydro-pyran-4-ol 
• 100-44-7 benzyl chloride 
• 1026022-15-0 O-triisopropylsilyl [2,4-di-O-benzyl-β-D-xylopyranosyl-(1->4)]-2,3-di-O-isopropylidene-α-L-rhamnopyranoside 
• 1026022-16-1 O-triisopropylsilyl {[2,3-di-O-acetyl-5-O-benzyl-β-D-apiofuranosyl-(1->3)]-2,4-di-O-benzyl-β-D-xylopyranosyl-(1->4)}-2,3-di-O-isopropylidene-α-L-rhamnopyranoside 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 87-72-9 D-Xylose 
• 100639-25-6 allyl 2,3-O-isopropylidene-α-L-rhamnopyranoside 

Downstream Products

• 1026022-18-3 O-triisopropylsilyl {[5-O-benzyl-2,3-di-O-benzylidene-β-D-apiofuranosyl-(1->3)]-2,4-di-O-benzyl-β-D-xylopyranosyl-(1->4)}-α-L-rhamnopyranoside 

Relevant academic research and scientific papers

TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants

QS-7-Api is an exceedingly potent immuno-adjuvant isolated from the bark of Quillaja saponaria. It is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccine clinical trials. Tedious isolation/purification protocols and uncertainty in its structural constitution have hindered the clinical development of QS-7. A chemical synthesis of QS-7-Api is described, providing structural verification of the adjuvant. A novel semisynthetic sequence to QS-7-Api has also been established, greatly facilitating access to QS-7 for preclinical and clinical evaluation.Copyright